Paragon Investment

The firm is led by founder 陳恒恕, who established Paragon after creating Taiwan's largest pharmaceutical clinical trial group. His operational background is central to the firm's investment process, which emphasizes hands-on assistance for portfolio companies. Decision-making authority appears concentrated under his direction.

The firm's deal flow is likely tied to the founder's deep network within Taiwan's healthcare and life sciences sectors, given his background leading a major clinical trial organization. Paragon Investment states it helps portfolio companies connect with markets and strategic partners, suggesting a sourcing model built on the founder's personal relationships and industry reputation.

Paragon Investment operates as an asset manager with a private equity and venture capital strategy, according to available records. While it was founded by an individual entrepreneur, it does not publicly present itself as a single family office. Its structure is that of an institutional investment firm deploying capital into early-stage companies.

The firm's stated focus is on direct investments in early-stage, seed, and start-up ventures. Public information does not indicate whether Paragon Investment makes commitments to other funds. Its model centers on direct company-building, leveraging the founder's experience to guide portfolio companies directly.

Paragon Investment targets the earliest phases of a company's lifecycle, specifically the early-stage, seed, and start-up stages. The firm operates a generalist venture strategy, indicating it does not limit itself to a single narrow vertical at the point of entry, but instead focuses on firms that can benefit from its operational network.